Wordt geladen...
Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
Brentuximab vedotin is a promising antibody–drug conjugate (ADC) targeting CD30 of tumor cells. It selectively delivers monomethyl auristatin E (MMAE) into CD30-expressing cells and induces tumor cell apoptosis. Various clinical trials have provided evidence that it is effective in relapsed or refra...
Bewaard in:
| Gepubliceerd in: | Drug Des Devel Ther |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove Medical Press
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4376183/ https://ncbi.nlm.nih.gov/pubmed/25848209 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S82007 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|